Mineral changes in osteoporosis - A review

被引：117

作者：

Faibish, Dan

Ott, Susan M.

Boskey, Adele L.

机构：

[1] Hosp Special Surg, Musculoskeletal Integr Program, New York, NY 10021 USA

[2] Univ Washington, Dept Med, Seattle, WA USA

来源：

CLINICAL ORTHOPAEDICS AND RELATED RESEARCH | 2006年 / 443期

关键词：

D O I：

10.1097/01.blo.0000200241.14684.4e

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

Bone mineral composition, crystallinity, and bone mineral content of osteoporotic patients are different from those of normal subjects. We review the evidence that these mineralization parameters contribute to the strength (fracture resistance) of bone and the methods that have been used to examine them. A specific example is provided from analysis of biopsies from the Multiple Outcomes in Raloxifene Evaluation trial. For the analyses, randomly selected biopsies from placebo, low-dose, and high-dose groups (n = 5 per group) obtained at time zero and 2 years after treatment were examined by infrared imaging spectroscopy. In all cases, comparable increases in mineral content were found, but there were no significant variations in mineral crystallinity.

引用

页码：28 / 38

页数：11

共 131 条

[31]

COHEN L, 1981, ISRAEL J MED SCI, V17, P1123

[32] Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis [J].